000154246 001__ 154246
000154246 005__ 20240229120024.0
000154246 0247_ $$2doi$$a10.3389/fimmu.2019.03004
000154246 0247_ $$2pmid$$apmid:31921218
000154246 0247_ $$2pmc$$apmc:PMC6934135
000154246 0247_ $$2altmetric$$aaltmetric:74545579
000154246 037__ $$aDKFZ-2020-00682
000154246 041__ $$aeng
000154246 082__ $$a610
000154246 1001_ $$aRoerden, Malte$$b0
000154246 245__ $$aNeoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
000154246 260__ $$aLausanne$$bFrontiers Media$$c2019
000154246 3367_ $$2DRIVER$$aarticle
000154246 3367_ $$2DataCite$$aOutput Types/Journal article
000154246 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1585656243_17923$$xReview Article
000154246 3367_ $$2BibTeX$$aARTICLE
000154246 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154246 3367_ $$00$$2EndNote$$aJournal Article
000154246 520__ $$aNeoantigens derive from non-synonymous somatic mutations in malignant cells. Recognition of neoantigens presented via human leukocyte antigen (HLA) molecules on the tumor cell surface by T cells holds promise to enable highly specific and effective anti-cancer immune responses and thus neoantigens provide an exceptionally attractive target for immunotherapy. While genome sequencing approaches already enable the reliable identification of somatic mutations in tumor samples, the identification of mutation-derived, naturally HLA-presented neoepitopes as targets for immunotherapy remains challenging, particularly in low mutational burden cancer entities, including hematological malignancies. Several approaches have been utilized to identify neoepitopes from primary tumor samples. Besides whole genome sequencing with subsequent in silico prediction of potential mutation-derived HLA ligands, mass spectrometry (MS) allows for the only unbiased identification of naturally presented mutation-derived HLA ligands. The feasibility of characterizing and targeting these novel antigens has recently been demonstrated in acute myeloid leukemia (AML). Several immunogenic, HLA-presented peptides derived from mutated Nucleophosmin 1 (NPM1) were identified, allowing for the generation of T-cell receptor-transduced NPM1mut-specific T cells with anti-leukemic activity in a xenograft mouse model. Neoantigen-specific T-cell responses have also been identified for peptides derived from mutated isocitrate dehydrogenase (IDHmut), and specific T-cell responses could be induced by IDHmut peptide vaccination. In this review, we give a comprehensive overview on known neoantigens in hematological malignancies, present possible prediction and discovery tools and discuss their role as targets for immunotherapy approaches.
000154246 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000154246 588__ $$aDataset connected to CrossRef, PubMed,
000154246 7001_ $$0P:(DE-HGF)0$$aNelde, Annika$$b1
000154246 7001_ $$0P:(DE-HGF)0$$aWalz, Juliane S$$b2
000154246 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2019.03004$$gVol. 10, p. 3004$$p3004$$tFrontiers in immunology$$v10$$x1664-3224$$y2019
000154246 909CO $$ooai:inrepo02.dkfz.de:154246$$pVDB
000154246 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154246 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000154246 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154246 9141_ $$y2019
000154246 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2017
000154246 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154246 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154246 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154246 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000154246 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000154246 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000154246 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000154246 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000154246 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154246 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154246 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154246 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2017
000154246 9201_ $$0I:(DE-He78)L801-20160331$$kL801$$lDKTK Tübingen$$x0
000154246 980__ $$ajournal
000154246 980__ $$aVDB
000154246 980__ $$aI:(DE-He78)L801-20160331
000154246 980__ $$aUNRESTRICTED